文献速递临床免疫质量管理与危急值

临床实验室实践中的黑天鹅:免疫分析方法干扰导致的分析误差

A Black Swan in clinical laboratory practice: the analytical error due to interferences in immunoassay methods.
PubMed 文献 · Clin Chem Lab Med · 2018-01-01

免疫分析方法的结果可受特异性或非特异性干扰影响,干扰发生率范围为0.4%至4.0%。干扰会损害免疫分析准确性,导致假阳性或假阴性结果,进而可能引起误诊或不恰当治疗。此类不规则分析误差难以通过常规实验室质量控制程序发现,在测试系统内可重现、临床看似合理且相对罕见;首要防线是使用抗干扰稳健性最高的免疫分析系统,其次应始终考虑免疫分析结果存在干扰的可能性,并识别高风险样本。

要点

  • 免疫分析干扰发生率范围为0.4%至4.0%,可导致假阳性或假阴性结果。
  • 干扰引起的分析误差无法被常规实验室质量控制程序检出,且在测试系统内可重现。
  • 应使用抗干扰稳健性最高的免疫分析系统,并始终考虑干扰可能性。

核心结论

  • 免疫分析方法的特异性或非特异性干扰可导致分析误差,发生率范围为0.4%至4.0%,可能引起误诊或不恰当治疗。
  • 此类不规则分析误差无法通过常规实验室质量控制程序检测,在测试系统内可重现、临床看似合理且相对罕见。

主要发现

  • 免疫分析结果可受特异性或非特异性干扰影响,干扰发生率范围为0.4%至4.0%。
  • 干扰会损害免疫分析准确性,导致测量误差,产生假阳性或假阴性结果。
  • 此类分析误差可能对患者照护产生严重影响,因其可导致误诊或不恰当治疗。
  • 与免疫分析方法相关的不规则分析误差难以识别,因其无法被常规实验室质量控制程序检测、在测试系统内可重现、临床看似合理且相对罕见。

临床怎么用

  • 第一道防线是在实验室实践中仅使用抗干扰稳健性最高的免疫分析系统。
  • 第二道防线是始终考虑免疫分析结果存在干扰的可能性。
  • 正确方法应侧重于识别高干扰风险的样本,需结合患者临床状况和文献数据对测试结果进行批判性审查,并考虑免疫分析系统的分析特性。
  • 免疫分析系统专家应努力寻找针对不规则分析误差的特异性且可靠的质量指标,以更好地检测和监测由特异性或非特异性干扰导致的错误免疫分析结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is well known that the results of immunoassay methods can be affected by specific or non-specific interferences, ranging from 0.4% to 4.0%. The presence of interference may greatly compromise the accuracy of immunoassay analyses causing an error in the measurement, producing false-positive or false-negative results. From a clinical point of view, these analytical errors may have serious implications for patient care because they can cause misdiagnosis or inappropriate treatment. Unfortunately, it is a very difficult task to identify the irregular analytical errors related to immunoassay methods because they are not detectable by normal laboratory quality control procedures, are reproducible within the test system, may be clinically plausible and are relatively rare. The first line of defense against erroneous results is to use in laboratory practice only immunoassay systems with the highest level of robustness against interference. The second line of defense is always taking into account the possibility of interference in immunoassay results. A correct approach should be addressed on identification of samples at high risk of interference. The attainment of this goal requires a critical review of the test result in relation to patient's clinical conditions and literature data, taking into account the analytical characteristics of the immunoassay system. The experts in immunoassay systems should make every effort to find some specific and reliable quality indicators for irregular analytical errors in order to better detect and monitor erroneous immunoassay results due to specific or non-specific interferences.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Clerico A, Belloni L, Carrozza C, et al. A Black Swan in clinical laboratory practice: the analytical error due to interferences in immunoassay methods. Clin Chem Lab Med. 2018. PMID: 29220884. doi:10.1515/cclm-2017-0881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。